Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Company

Eukarÿs


Pépinière Genopole Entreprises
4, rue Pierre Fontaine – Genopole Campus 3
91058 EVRY-COURCOURONNES Cedex – FRANCE
Email: contact@eukarys.com

Philippe JAIS: CEO
Web Site >
Eukarÿs - Genopole's company Eukarÿs - Genopole's company

#Biomanufacturing / Pharmaceutical Services #Therapeutics

  • Lentivirus
  • AAV
  • Vaccines
  • Bioproduction
  • Virus
  • C3P3 technology
  • Messenger RNA
  • Synthetic biology

Field of Activity


By means of its autonomous messenger RNA synthesis platform, Eukarÿs develops 1) systems for the bioproduction of viruses and recombinant proteins and 2) preventative vaccines for viral infectious diseases and treatments in immuno-oncology.

BACKGROUND
Using a synthetic biology approach, Eukarÿs has developed C3P3, an unprecedented eukaryotic artificial expression system. C3P3 is based on the use of an artificial RNA polymerase, which produces mature eukaryotic mRNA. The system is currently in its fourth generation. Progressive improvements in its performance enabled the use of C3P3 first for the development of bioproduction tools and thereafter for vaccines.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
Eukarÿs’s bioproduction tools can currently be used transiently with very good yields. The system is currently used by many academic molecular-virology laboratories and by pharmaceutical companies for the production of wild-type and recombinant viruses. These tools are available under a license agreement. Eukarÿs intends to launch the development of a stable, recombinant-protein production system in 2023.
The company’s synthetic gene vaccine platform is based on the administration of synthetic DNA coding for both the C3P3 enzyme and the gene(s) of interest. This synthetic DNA is produced using Eukarÿs’s proprietary technology. Synthetic DNA enables self-amplification of antigen expression by means of multiple amplification loops, which increase its efficiency. This vaccine system is in the non-regulatory clinical phase, but also in the development phase for its therapeutic immuno-oncological use in primary liver cancer.

CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS
Improved performance of the C3P3 system now in its fourth generation.
Development of tools for the bioproduction of recombinant viruses. Agreement with a major actor in the pharmaceutical industry (confidential).
Development of an auto-amplification technology used for synthetic gene vaccination.
Ongoing optimization of the synthetic DNA production technology used for vaccinal purposes.

COLLABORATIONS SOUGHT
License agreements or partnerships for the use of Eukarÿs’s tools for the bioproduction of wild-type viruses, recombinant viruses or recombinant proteins.
Licensing agreements or partnerships for the development of synthetic gene vaccines and immuno-oncology therapeutics.

  • Further information

    4 patents
    3 staff members
    Strengths
    A unique, patented and efficient eukaryotic expression technology for autonomous production of mRNA in vivo.
    Innovation assets
    A unique and powerful eukaryotic expression system. Innovative tools for the widespread use of bioproduction. A promising vaccine technology, also in the evaluation phase in immuno-oncology.

Share
Genopole’s Companies

#Biomanufacturing / Pharmaceutical Services


In same field

Kyron.Bio - Genopole's Company

Kyron.Bio

Kyron.Bio is a biotech company using synthetic biology to produce new therapies with high yield, activity, and stability standards.

Discover
Nutropy - Genopole's company

Nutropy

Nutropy develops gourmet French cheese alternatives that are more sustainable and better for our health and animal welfare.

Discover
STH Biotech - Genopole's company

STH Biotech

STH BIOTECH is developing an innovative cannabis-based process for the reliable and sustainable production of active compounds for the well-being and healthcare sectors.

Discover
Synovance - entreprise généopolitaine

Synovance

Synovance has developed a revolutionary synthetic genomics platform for the conception of robust industrial bioproduction strains.

Discover
DeepTope - Genopole's company

Deeptope

– Characterization of antigen / antibody interactions (epitope / paratope) – Optimization of therapeutic antibodies

Discover
Proteinea - Genopole's company

Proteinea

Production as a service (PaaS) platform capable of producing recombinant proteins & enzymes cheaper and on a scale.

Discover
Altar - entreprise génopolitaine - intégre le groupe Ginko Bioworks

Altar

Altar / GinkGo Bioworks is a specialist in the conception and operation of automated fluidic continuous culture systems for adaptive laboratory evolution and the development of microbial strains for industry.

Discover
Yposkesi - Genopole's Company

Yposkesi

YposKesi is the first French company to develop and manufacture gene and cell therapy products for rare diseases.

Discover
Watchfrog Laboratory - Genopole's company

WatchFrog

WatchFrog markets in vivo biotechnological solutions for environmental risk assessment and the evaluation of the therapeutic, toxic or pollutant potential of all types of chemical, cosmetic or pharmaceutical compounds.

Discover
Texcell - Genopole's Company

Texcell

Texcell offers fully GLP- and GMP-compliant viral safety testing and immunomonitoring services.

Discover
Hybrigenics - Genopole's company

Hybrigenics Services

Hybrigenics Services proposes fee-for-services R&D support and provides innovative technological platforms for i) protein interaction studies (protein-protein, drug-protein, mechanisms of action) and ii) selection and validation of VHH antibodies.

Discover
Genosafe - Genopole's Company

Genosafe

GenoSafe is a full contract research and consulting organization specialized in evaluating the quality, safety and efficacy of innovative biological products. Our goal is to enable our clients to move their products along clinical development rapidly and efficiently.

Discover
ABOLIS - entreprise génopolitaine

Abolis Biotechnologies

Abolis develops custom-order microorganisms able to produce molecules of interest via fermentation for the health, nutrition, chemistry and cosmetics sectors.

Discover
View all >
With the support from
Région île de France